NCT00802737View on ClinicalTrials.gov

Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)

PHASE4CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

September 30, 2011

Study Completion Date

May 31, 2013

Conditions
Leukaemia, Lymphocytic, Chronic
Interventions
DRUG

Ofatumumab

Eight once weekly infusions (1 x 300 mg + 7 x 2000 mg), then 2000 mg once monthly for two years

Trial Locations (2)

SE-701 85

GSK Investigational Site, Örebro

SE-171 76

GSK Investigational Site, Stockholm

Sponsors

Lead Sponsor

GlaxoSmithKline

Collaborators (1)

Genmab
All Listed Sponsors
collaborator

Genmab

INDUSTRY

lead

GlaxoSmithKline

INDUSTRY

NCT00802737 - Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL) | Biotech Hunter | Biotech Hunter